TY - JOUR
T1 - Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma
T2 - a review of options for and against
AU - Richardson, Paul G.
AU - Holstein, Sarah A.
AU - Schlossman, Robert L.
AU - Anderson, Kenneth C.
AU - Attal, Michel
AU - McCarthy, Philip L.
N1 - Funding Information:
Medical writing assistance was provided by Kristina Hernandez, PhD, and Peter Simon, PhD, of MediTech Media, Ltd, and was sponsored by Celgene Corporation.
Funding Information:
PG Richardson has served on advisory committees for Celgene, Novartis, Millennium, Takeda, Gentiuum S.p.A., and Jazz Pharmaceuticals and reports research funding from Gentium S.p.A. and Jazz Pharmaceuitcals. SA Holstein has served on advisory committees for Celgene, Takeda, and Amgen and has received consulting fees from Celgene. RL Schlossman has served on advisory boards for Millennium, Takeda, Novartis, and Celgene. KC Anderson reports being the scientific founder of Acetylon, OncoPep and C4 Therapeutics and has served in consulting/advisory roles for Celgene, Gilead, Millennium, and Takeda. M Attal reports no conflicts of interest. PL McCarthy received honoraria from Bristol-Myers Squibb, Celgene, Sanofi, Takeda, and Binding Site and research funding from Celgene and reports advisory committee/review panel/board membership for Bristol-Myers Squibb, Celgene, Sanofi, Takeda, Binding Site, and Karyopharm. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/12/12
Y1 - 2017/12/12
N2 - Introduction: Lenalidomide has multifaceted antimyeloma properties, including direct tumoricidal and immunomodulatory effects. Several randomized controlled trials have demonstrated improved patient outcomes with lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). Currently, single-agent lenalidomide is the only approved post-ASCT maintenance therapy in the United States and European Union for patients with NDMM. Areas covered: This review article summarizes the efficacy and safety data of lenalidomide maintenance, as monotherapy and in combination with other agents, following ASCT in patients with NDMM. In addition, emerging therapies with newer agents in this setting are discussed. Expert opinion: Following ASCT, maintenance therapy with lenalidomide until progressive disease is an effective and well-tolerated regimen and represents the standard of care for patients with NDMM. Studies evaluating maintenance with lenalidomide in combination with next-generation proteasome inhibitors, monoclonal antibodies, and histone deacetylase inhibitors may further improve patient outcomes.
AB - Introduction: Lenalidomide has multifaceted antimyeloma properties, including direct tumoricidal and immunomodulatory effects. Several randomized controlled trials have demonstrated improved patient outcomes with lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). Currently, single-agent lenalidomide is the only approved post-ASCT maintenance therapy in the United States and European Union for patients with NDMM. Areas covered: This review article summarizes the efficacy and safety data of lenalidomide maintenance, as monotherapy and in combination with other agents, following ASCT in patients with NDMM. In addition, emerging therapies with newer agents in this setting are discussed. Expert opinion: Following ASCT, maintenance therapy with lenalidomide until progressive disease is an effective and well-tolerated regimen and represents the standard of care for patients with NDMM. Studies evaluating maintenance with lenalidomide in combination with next-generation proteasome inhibitors, monoclonal antibodies, and histone deacetylase inhibitors may further improve patient outcomes.
KW - Immunomodulatory
KW - lenalidomide
KW - maintenance therapy
KW - multiple myeloma
KW - stem cell transplant
UR - http://www.scopus.com/inward/record.url?scp=85037697982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037697982&partnerID=8YFLogxK
U2 - 10.1080/14656566.2017.1409207
DO - 10.1080/14656566.2017.1409207
M3 - Review article
C2 - 29172855
AN - SCOPUS:85037697982
SN - 1465-6566
VL - 18
SP - 1975
EP - 1985
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 18
ER -